
Regeneron, Sanofi Withdraw FDA Application For Cancer Drug’s Expanded Use
Libtayo is an anti-cancer drug developed by Regeneron Pharmaceuticals Inc. and Sanofi for advanced cervical cancer patients. The two companies withdrew their application for expanded use with the U.S. drug regulator. In a statement on Friday, the companies said that their application to use monoclonal antibodies for treatment in second-line patients was withdrawn “because the










